Researchers have found a useful side effects of ozmpic and similar drugs: they can be effective in controlling alcohol overconsuration.

A new study published in the Jama Psychiatry Journal found that the semaglutide (Maunjaro, Ozmpic, Rybellas and Vagovi) sold under the brand names can help curb the craving of alcohol.

However, the clinical trial consisted only 48 participants and were held in a period of nine weeks. Selected participants already dealt with alcohol use disorder (AUD) – a condition that makes it difficult to control alcohol consumption. Women participants reported to drink more than seven drinks in a week, while male participants consumed 14 within a month. He also reported two or more heavy drinking days (five drinks for men at a time and four drinks for women).

During the test, half the patients received a low dose of semaglutide on a weekly basis, while the other half found a placebo. Participants of the Semaglutide group experienced a decrease of about 30 percent of the amount of alcohol during the drinking days of the second month of treatment. In contrast, the Placebo group saw only 2 percent decrease during the same period. In addition, 40 percent of the participants in the Semaglutide group reported that there was no ‘day of any heavy drinking’ compared to 20 percent in the placebo group.

However, it was observed that Semaglutide did not affect the number of days that people consumed alcohol; Only the amount consumed was low. The test found that Semaglutide was not affected how many days of the week people chose to drink alcohol – just when they drank, they drank less.

No one can ignore many boundaries of new studies. For example, researchers have not yet been determined how semaglutide alcohol reduces craving. Is this due to common side effects like nausea, which naturally discourage drinking? Or does the drug changes brain activity and makes alcohol less attractive, which is similar to its effect on food?

Additionally, the study did not include participants without additional body weight. Only one of the participants had BMI under 24.9 (25 to 29 is considered over weight, and is thicker after 30); Thus, whether semaglutide should be used in people without weight issues, there is still a question.

It is also to be studied what happens to a person with a disorder using alcohol, when they stop taking the medicine. Large trials in a long period definitely require assessment of whether (and how) semaglutide can actually help with alcohol addiction.

Semaglutide, a GLP -1 receptor agonist drug, was originally developed as an anti -diabetic drug. It has now gained popularity for its important results for weight loss. This enzyme mimics the action of GLP-1 and reduces appetite through the brain routes and slows down the gastric to empty food in the intestine. It promotes the feeling of early perfection and therefore leads to calorie intake and later weight loss.

As it continues global discussion as a miraculous drug for its dual advantage – insulin production and significant weight loss – many side effects (some rather stunning) have emerged. Minor symptoms include nausea, diarrhea, vomiting and upper abdominal pain. Some severe side effects may lead to vision issues, pancreatitis, abdominal paralysis, gallbladder issues and allergic reactions. Some patients may also face Ilyas (a situation where the intestines are no longer able to contract, so the waste is not able to go out of the body).

In the context of amazing effects, people have reported an increase in fertility (as suggested by the ozapic baby boom) and delayed aging.